Topotecan-based combined chemotherapy for refractory or relapsed hematologic malignancies.
- Author:
De-pei WU
1
;
Xiao-wen TANG
;
Ai-ning SUN
;
Hui-ying QIU
;
Zheng-zheng FU
;
Rao MA
;
Chang-geng RUAN
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Bone Marrow; drug effects; Child; Female; Humans; Leukemia; drug therapy; Lymphoma, Non-Hodgkin; drug therapy; Male; Middle Aged; Topotecan; administration & dosage; adverse effects
- From: Chinese Journal of Oncology 2003;25(6):599-601
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and toxicity of topotecan-based combined chemotherapy for refractory or relapsed hematologic malignancies.
METHODSTwenty-one patients with refractory or relapsed acute leukemia (AL), non-Hodgkin's lymphoma (NHL) or high risk myelodysplastic syndrome (MDS) were treated by topotecan with cytarabine, amsacrine or cyclophosphamide. All patients received a single course as salvage therapy.
RESULTSThe overall response rate of one course was 61.9% with 9/21 (42.9%) CR and 4/21 (19%) PR. Severe myelosuppression was observed in all patients. Agranulocytic time was 12.6 days in AL and 7.5 days in NHL. Sixteen of 21 patients received G-CSF 300 micro g/d All patients received supportive treatment of transfusion. Fever and documented infection developed in 15 patients. Non-hematologic toxicity was mild.
CONCLUSIONTopotecan-based combined chemotherapy has significant antitumour activity and acceptable toxicity as salvage therapy for high risk hematologic malignancies.
